TEJ-KOHLI-FOUNDATION
10.10.2019 08:02:07 CEST | Business Wire | Press release
On World Sight Day, the Tej Kohli Foundation says that a focus on new technologies is needed to accelerate the global mission to end curable corneal blindness worldwide. The Foundation is currently funding the clinical trials and development of a ‘liquid biosynthetic’ solution that could offer an accessible, scalable and affordable solution to corneal blindness that would be relevant to many of the 12 million people worldwide who suffer from this type of blindness.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191009005535/en/
The thesis of the Tej Kohli Foundation is that humanitarian efforts the world over will be greatly advanced by exponential growth technologies such as AI, robotics and genomics. The Foundation behaves like a venture fund by backing, incubating, acquiring and accelerating the development of technology solutions. Only successful projects secure further funding support, leaving the Foundation agile to back the projects that will have the greatest impact.
Blindness is heavily impacted by poverty. According to the WHO, 14 million of the 39 million people who are blind live in India. 12.7 million people are currently waiting for a cornea transplant, including 6 million in India. The Tej Kohli Foundation’s ‘Cornea Institute’ at the LV Prasad Eye Institute in Hyderabad already conducts thousands of corneal transplants every year using donor cornea, largely for free. The Foundation recently cured five brothers and sisters in the same family from Rajasthan who had all been suffering with long-term visual impairment.
But the limited supply of donor cornea and the need for invasive surgery means that worldwide less than 1 in 70 will receive a cornea transplant each year. Artificial cornea or keratoprotheses are expensive and can cost up to US$20,000. The Tej Kohli Foundation is backing the development of technological solutions, because ending corneal blindness will require an affordable, accessible and scalable solution that does not rely on transplantation.
The Tej Kohli Foundation previously backed methods of synthesising artificial cornea from yeast and peptides, but new advances mean it has switched this funding to the development of the liquid biosynthetic, which aims to work by causing the regeneration of corneal tissue. The pro-regeneration tissue replacement could avoid the need for expensive corneal grafting and be applied in less than thirty minutes to fill a perforation or to repair a corneal ulcer.
In July 2018 the Tej Kohli Foundation also made a $2m gift to Massachusetts Ear and Eye, a teaching hospital of Harvard Medical School, to fund innovation in research into nano-string and DNA-sequencing technologies for early diagnostics and prevention, as well as ‘GelCORE,’ an adhesive biomaterial for replacing corneal tissue.
Michael Macfarlane, spokesperson for the Tej Kohli Foundation:
“There are limits to the number of corneal transplants that can take place each year, especially in poor and remote rural areas. The Tej Kohli Foundation is a global focal point for scientists and others who are developing pioneering treatments in this field. Our mission is to work with a range of partners in our goal to eliminate corneal blindness by 2035.”
Tej Kohli, co-Founder of the Tej Kohli Foundation:
“Eliminating corneal blindness is what I am most passionate about. I favour a venture-led approach to philanthropy whereby we bring people together and provide the funding to accelerate the development of solutions that might bring us a step closer to ending corneal blindness. The way that we run our Foundation is directly aligned with how we manage our commercial ventures and investments, and this approach means we can drive greater progress from every pound or dollar or rupee that we spend on achieving our mission.”
Find out more about the Tej Kohli Foundation at: http://www.tejkohlifoundation.com
A video about a family of five siblings having their long-term visual impairment cured by the Tej Kohli Foundation is available to embed using this link: https://youtu.be/Pmcb9pRxOSs
A video interview with Wendy and Tej Kohli in which they talk about the work of the Tej Kohli Foundation is available to embed using this link: https://youtu.be/JgOO4Cs-jnw
A video about the Tej Kohli Cornea Program is available to embed using this link: https://youtu.be/2zUBtj6H7GM
A video about the Tej Kohli Cornea Institute is available to embed using this link: https://youtu.be/lkZmI8lkpm8
About The Tej Kohli Foundation
The Tej Kohli Foundation was launched by Wendy and Tej Kohli in 2005 as a focal point for their global philanthropic endeavours. The Foundation includes:
- Cornea Institute: which since 2016 has seen more than 180,000 outpatients and carried out 17,000+ cornea replacement surgeries, largely for free.
- Cornea Program: which funds innovation in research to cure corneal blindness at Mass. Eye and Ear, a teaching hospital of Harvard Medical School.
- Applied Research: which is engaged in the acquisition and development of new technologies that have the potential to substantially reduce corneal blindness globally.
- Impact Initiatives: which supports projects in underserved communities where direct interventions can have a sustained and positive impact upon individual lives.
http://www.tejkohlifoundation.com
About Tej Kohli
Tej Kohli is a London-based investor and entrepreneur with a well-publicized mission to cure corneal blindness worldwide by 2035. He first rose to success during the dotcom boom selling technology solutions and e-commerce payments software before becoming a real estate investor in technology hubs. He now focuses on high-impact investments into AI, robotics, biotech and genomics ventures. Tej Kohli is a Distinguished Alumni of the Indian Institute of Technology in Kanpur (IITK) where he completed a degree in Electrical Engineering.
END
View source version on businesswire.com: https://www.businesswire.com/news/home/20191009005535/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
Unpack ’26 sommerrejsetrends: Flere vælger indenlandske rejser, når de tænker mere bevidst over deres rejsevalg21.5.2026 12:35:00 CEST | Pressemeddelelse
Rejsebranchens førende databrevne trendrapport lancerer sin første sommerudgave nogensinde – Unpack ’26 Summer: The Trends in Travel I dag har Hotels.com udgivet Unpack ’26 Summer: The Trends in Travel, den nyeste udgave af virksomhedens førende trendrapport i rejsebranchen, som viser, hvordan rejseadfærd former sommerens rejsevalg. Efterspørgslen på indenlandske rejser præger sommerens ferieplanlægning. Interessen på sociale medier for indenlandske ferier er globalt steget med 77% sammenlignet med sidste år, og 44% af danske rejsende planlægger en indenlandsk rejse denne sommer*. Fra store sportsbegivenheder og koncerter til rejser inspireret af film og tv bygger Unpack ’26 Summer på indsigter fra den årlige hovedrapport Unpack ’26: The Trends in Travel™ for at fremhæve, hvor rejsende tager hen denne sommer. HHver tendens bygger på førstehåndsdata fra Hotels.com® kombineret med indsigter fra rejsende og overvågning af sociale medier. “Denne sommer bliver der stadig rejst – men på nye
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
